SCHEMBL3823481

SCHEMBL3823481

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1ncncc1-c1cc(NC2CC2)ncn1

nearest known ligand 0.64

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.64
TEK Q02763 3/20 0.64
LCK P06239 4/20 0.58
SRC P12931 4/20 0.58
INSR P06213 2/20 0.58
LYN P07948 2/20 0.58
HCK P08631 1/20 0.58
BRAF P15056 12/20 0.57
MAPK14 Q16539 2/20 0.56
BTK Q06187 1/20 0.55
ABL1 P00519 2/20 0.52
CSF1R P07333 2/20 0.52
KIT P10721 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824106 0.95 KDR (0.60) KDRTEKLCKSRCINSR
SCHEMBL3823342 0.94 LCK (0.65) KDRTEKLCKSRCINSR
SCHEMBL3824880 0.90 KDR (0.74) KDRTEKLCKSRCINSR
SCHEMBL3829573 0.90 KDR (0.68) KDRTEKLCKSRCBRAF
SCHEMBL3824997 0.89 KDR (0.67) KDRTEKLCKSRCBRAF
SCHEMBL13897963 0.88 KDR (0.48) KDRTEKLCKSRCINSR
SCHEMBL3824874 0.88 KDR (0.65) KDRTEKLCKSRCINSR
SCHEMBL3824167 0.88 KDR (0.65) KDRTEKLCKSRCBRAF
SCHEMBL3589391 0.87 KDR (0.59) KDRTEKLCKSRCINSR
SCHEMBL27740911 0.87 BTK (0.57) KDRTEKLCKSRCINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US claimed
EP-1981870-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-22 EP claimed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO claimed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
EP-1981870-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-22 EP disclosed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO disclosed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS SRC, BMX, FYN KDR 95/4885TEK 375/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.